Jump to content

HLP005

Add links
From Wikipedia, the free encyclopedia
HLP005
Clinical data
Other namesHLP005; HLP-005; CYB005; CYB-005; Deuterated phenethylamine; Deuterated phenethylamine derivative
Drug classSerotonin receptor agonist; Serotonergic psychedelic; Antiinflammatory drug[1]

HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of CNS disorders and neuroinflammation.[2][3][1]

Interactions

[edit]
See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

HLP005 acts as a serotonin receptor agonist and is a serotonergic psychedelic.[2][1] In addition, HLP005 may also inhibit serotonin and dopamine reuptake.[1]

Chemistry

[edit]
Structure of CYB2108D, a deuterated analogue of 2C-T-36 (CYB2108; CYB210010).[4][5]

HLP005 is a phenethylamine derivative and a deuterated compound.[2][3][1] The exact chemical structure of HLP005 does not yet seem to have been disclosed.[2][1] However, it appears to be closely related to CYB210010 (CYB2108; 2C-T-36 or 2C-T-TFM), which itself is non-deuterated.[6][7][8] In addition, HLP005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.[2][6][4] Some notable phenethylamines patented by Helus Pharma include the non-deuterated CYB2108 (2C-T-36) and its deuterated form CYB2108D (fully deuterated methoxy groups at 2 and 5 positions).[4][5]

Research

[edit]

HLP005 is under development by Helus Pharma (formerly Cybin).[2][3][1] As of November 2025, it is in the preclinical research stage of development for treatment of CNS disorders.[2][3] The drug was also under development for treatment-resistant psychiatric disorders, but development for this indication was discontinued in November 2025.[2] Other related drugs under development by Helus Pharma include the deuterated tryptamines HLP003 (CYB003) and HLP004 (CYB004).[1][9]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci. 23 (24) 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419. Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs.: [...] Drug Name: Phenethylamine derivative (CYB005): Chemical Structure: *. Target type: –. Method of Action: CYB005 inhibits serotonin and dopamine transporters within the synaptic cleft. [...] These drugs generally bind to CNS G-protein receptors within the 5-HT family, such as 5-HT1A, 5-HT2A, and 5-HT2B, and act agonistically [9,13–15,17,18]. Additionally, two of these, ecstasy and CYB005 (phenethylamine derivative [20]), block the reuptake of serotonin, increasing the serotonin levels within the synaptic cleft [12,21,22]. [...] According to preclinical data, CYB005, a phenethylamine derivative, aims to inhibit serotonin transporters within the synaptic cleft [20–22]. [...] Studies on [...] CYB005 [...] were not found in the literature search, so this information was obtained through the websites of their respective pharmaceutical companies. [...] Table 2. Highlights of the psychoceutical benefits.: Drug: CYB005 (Phenethylamine derivative). Benefit: Treats neuroinflammation and psychiatric conditions. [...] Three [deuterated] drugs that researchers have been working on are [...] CYB005 (for neuroinflammation). [...] Finally, CYB005 is a phenethylamine derivative currently in preclinical development [55], which has the potential to treat neuroinflammation and psychiatric conditions [20]. [...] Of the 20 drugs, [...] CYB005 [...] do not currently have completed clinical trials.
  2. ^ a b c d e f g h "CYB 005". AdisInsight. 28 October 2024. Retrieved 10 November 2024. CYB 005 is a phenethylamine derivative is being developed by Cybin for the treatment of treatment resistant psychiatric disorders.
  3. ^ a b c d "Delving into the Latest Updates on CYB-005 with Synapse". Synapse. 1 November 2024. Retrieved 10 November 2024.
  4. ^ a b c "Therapeutic phenethylamine compositions and methods of use". Google Patents. 18 August 2021. Retrieved 10 November 2024.
  5. ^ a b "2-[2,5-Bis(trideuteriomethoxy)-4-(trifluoromethylsulfanyl)phenyl]ethanamine". PubChem. Retrieved 2 April 2026.
  6. ^ a b "Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program". Yahoo Finance. 24 October 2024. Retrieved 10 November 2024.
  7. ^ Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". J Med Chem. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.
  8. ^ Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, Morgan M, Mueller T, Reichelt A, Pathare P, Stang E, Nivorozhkin A (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (299–299). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
  9. ^ Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=HLP005&oldid=1346799111"